A 56-year-old man was referred with asymptomatic elevation of pancreatic hydrolase levels. Magnetic resonance imaging (MRI) delineated a pancreatic lesion with a low T1 and high T2 signal (Fig. 1). Endoscopic ultrasound (EUS) found an oval, well-defined, isoechogenic, homogeneous mass in the pancreatic parenchyma, without any vascular invasion and no locoregional lymph nodes (Fig. 2). Fine-needle aspiration (FNA) showed small epithelioid cells. Immunostaining was positive for antichromogranin, antisynaptophysin, and anti-KI-67 (5%), and a few cells were positive for anti-CD56. This was consistent with a neuroendocrine tumor (NET).

Octreotide positron emission tomography combined with computed tomography (PET-CT) showed a focal uptake into the pancreas without any other nonphysiological uptake (Fig. 3). CA19–9 and chromogranin levels were normal.

Caudal pancreatectomy with spleen preservation was performed. Histological examination found no proof of NET but did reveal an intrapancreatic accessory spleen (IPAS) (Fig. 4). The postoperative period and follow-up were satisfactory.

Accessory spleens may be found in 15% of the population but are rarely located in the pancreatic tail (17%) [1]. Most IPASs have a homogeneous contrast-enhanced appearance on CT and MRI, sharing features with hypervascular lesions (such as NETs) [1]. Octreotide scans have a high sensitivity for detection of gastrointestinal NET (70%–95%). The somatostatin receptors on the surface of splenic lymphocytes may lead to false diagnosis of NET [2]. Nuclear scintigraphic investigations such as those with $^{99m}$Tc sulfur colloid can help in identifying IPAS [3]. Ultrasound endoscopists should be aware of this entity (IPAS) in order to avoid unnecessary surgery, even when FNA shows cells with NET characteristics.

CD8 immunostaining of splenic sinus endothelial cells can help in confirming the diagnosis, as done retrospectively on FNA material in our patient [5].

Competing interests: None
References


Bibliography

Endoscopy 2011; 43: E221–E222
© Georg Thieme Verlag KG Stuttgart · New York · ISSN 0013-726X

Corresponding author

E. Toussaint, MD
Gastroenterology
Clinic of Medical Oncology
Institut Jules Bordet
1 rue Héger-Bordet
1000 Brussels
Belgium
Fax: +32-2-5380858
emmanuel.toussaint@bordet.be